Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dizal’s JAK1 Inhibitor NDA Accepted for China Review as PTCL Therapy

publication date: Sep 15, 2023

Shanghai Dizal Pharma reported its NDA for golidocitinib was accepted by China’s CDE for review as a treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor that showed efficacy in a global, multicenter pivotal study. In a trial that enrolled 112 r/r PTCL patients, golidocitinib produced an ORR of 44% and a CRR of 24%. One month ago, Dizal announced that its lead drug, sunvozertinib, was approved for China use as a second line therapy for NSCLC with EGFR exon 20 insertion mutations. More details.... 

Stock Symbol: (SHA: 688192)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here